Verition Fund Management
CAPR icon

Verition Fund Management’s Capricor Therapeutics CAPR Stock Holding History

Verition Fund Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,705
Closed -$186K – 3773
2025
Q2 		$186K Sell
18,705
-28,946
-61% -$306K ﹤0.01% 3384
2025
Q1 		$452K Buy
+47,651
New +$661K ﹤0.01% 2644

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verition Fund Management's CAPR Position: Q3 2025 in Review

Verition Fund Management sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 18,705 shares — an estimated $186K sold.

Verition Fund Management first reported a position in CAPR in Q1 2025 and held it in 2 quarters. The position peaked at $452K in Q1 2025. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

  • Verition Fund Management reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 18,705 Capricor Therapeutics shares in Q3 2025, an estimated $186K.
  • Verition Fund Management first reported a position in Capricor Therapeutics in Q1 2025 and held it in 2 quarters.
  • Verition Fund Management's Capricor Therapeutics position peaked at $452K in Q1 2025.
  • 115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.